Dermal Penetration of the Titanium Dioxide in Anthelios SX SPF40 Cream
1 other identifier
interventional
26
1 country
1
Brief Summary
To determine the penetration of micronized and pigmentary TiO2 in Formulas 283419 2 and 760.001 into the stratum corneum of Compromised (Induced Sunburn) human skin via skin stripping of human subjects.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_4
Started Dec 2009
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 25, 2009
CompletedFirst Posted
Study publicly available on registry
November 30, 2009
CompletedStudy Start
First participant enrolled
December 1, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2009
CompletedJune 14, 2011
November 1, 2009
Same day
November 25, 2009
June 13, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Determine degree of penetration of TiO2 down to 16 -20 tape strips of human skin
Single application
Interventions
Topical cream
Eligibility Criteria
You may qualify if:
- All subjects must:
- be between the ages of 18 and 65.
- agree to not participate in any other product evaluations or clinical evaluations during the course of this study.
- have read, understood and signed an Informed Consent Form.
- have intact skin in the treatment area.
- have fair skin - Skin Types I, or II - as defined in Appendix II.
- be able to understand and willing to follow all study procedures and restrictions.
You may not qualify if:
- Subjects will be excluded from participating in the study if they:
- are female and are pregnant or lactating \[must be using an acceptable method of birth control if of child bearing potential\].\*
- exhibit any visible symptoms of skin disease, such as psoriasis or eczema, or skin abnormality (including active dermal lesions, uneven skin tone or scars) which might interfere with interpretation of the study results. The presence of nevi, blemishes, or moles will be acceptable if, in the Investigator's judgement, they will not interfere with the study results or skin stripping procedures.
- have a history of allergic responses to sunscreens or other products similar to those included in this study.
- have very dry or scaly skin on the test site.
- have diabetes.
- have a history of abnormal responses to sunlight, such as a phototoxic or photoallergic response.
- have an existing sunburn or suntan, or been to a tanning booth which would interfere with interpretation of the study results.
- have used self tanners within the past two weeks.
- have excessive hair at the test site area which could, in the opinion of the investigator, interfere with the interpretation of the results.
- have participated in a research drug trial or patch test within six weeks of beginning this study.
- have a known sensitivity to Scotch 600 Transparent Tape.
- are currently receiving, or within the past two weeks received, topical or systemic medication which could, in the opinion of the investigator, interfere with the interpretation of the results, affect the safety of the subject, or which may change the body's response to ultraviolet light.
- are currently taking any of the drugs listed on the next page. In addition, the use of St. John's Wort or other similar dietary supplements, aspirin or OTC ibuprofen is contraindicated for the duration of the study. Low dose daily aspirin use, 81 mgs, taken for heart attack prevention is excluded.
- Acceptable methods of birth control that can be used during the course of the study are: oral contraceptive pill, intrauterine device, patch, injection, condom with spermicide, partner vasectomy, bilateral tubal ligation, abstinence or evidence of non childbearing potential (i.e., post-menopausal \[one year without menstrual period\], hysterectomy or bilateral ovariectomy).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Loreal USAlead
Study Sites (1)
Hill Top Research
Winnipeg, Manitoba, R3L2W2, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- NONE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
November 25, 2009
First Posted
November 30, 2009
Study Start
December 1, 2009
Primary Completion
December 1, 2009
Study Completion
December 1, 2009
Last Updated
June 14, 2011
Record last verified: 2009-11